Yvonne Greenstreet, Alnylam CEO (Alnylam)

Ear­ly re­sults from Alzheimer’s study set stage for Al­ny­lam’s ex­pan­sion in­to brain dis­eases

Al­ny­lam Phar­ma­ceu­ti­cals un­veiled the first ev­i­dence that its RNA in­ter­fer­ence tech­nol­o­gy can dra­mat­i­cal­ly re­duce lev­els of pro­teins linked to Alzheimer’s dis­ease, an ear­ly but in­trigu­ing re­sult that could prompt new ap­proach­es to treat­ing the mem­o­ry-rob­bing con­di­tion.

On Wednes­day, the Cam­bridge, MA-based biotech and its part­ner Re­gen­eron an­nounced pre­lim­i­nary da­ta from their Phase I study of their ex­per­i­men­tal drug dubbed ALN-APP. The drug was de­signed to si­lence the ex­pres­sion of a brain pro­tein called amy­loid pre­cur­sor pro­tein, a fore­run­ner to the amy­loid pro­teins and plaques that ac­cu­mu­late in peo­ple with Alzheimer’s.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.